ReviewCancers2025
Suicidal Ideation, Suicide Attempts, and Suicide Mortality in Cancer: An Overview of Systematic Reviews with Meta-Analysis.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methods of Suicide Used by People With Cancer: A Scoping Review.Psycho-oncology · 2026Article
- Pain and Suicide Behavior in Cancer Patients: Implications for Personalized Treatment-A Systematic Review.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundthis overview of systematic reviews with meta-analysis summarized the epidemiology of suicide in cancer, mainly focused on prevalence, incidence, and risk.
methodsthe CINAHL (via EBSCOhost), Embase, PsycINFO (via ProQuest), and PubMed databases were searched from inception to February 2024. AMSTAR 2 evaluated the methodological quality of reviews. The degree of overlap between reviews was calculated.
resultsTwelve systematic reviews with meta-analysis were included. The prevalence of suicidal ideation in prostate cancer was 9.85% (95%CI 7.31-12.70%). The relative risk of suicidal ideation in prostate cancer was 2.01 (95%CI: 1.52-2.64) in comparison to controls without this type of cancer during the first 12 months after diagnosis. Furthermore, the risk of suicidal ideation was higher among individuals with bladder cancer in comparison to people without this clinical condition (HR 1.90, 95%CI 1.29-2.81). The crude suicide mortality rate per 100,000 person-years in prostate cancer was 47.1 per 100,000 person-years (95%CI 39.85-54.96). Incidence suicide death per 100,000 person-years was higher in sarcoma (60.99 per 100,000 person-years, 95%CI 17.37-214.19), esophagus (87.71 per 100,000 person-years, 95%CI 27.42-280.54), and pancreas (75.39 per 100,000 person-years, 95%CI 41.80-135.97). Finally, the standardized mortality ratio by suicide was higher in the pancreas (SMR 6.42, 95%CI 1.60-25.76), bone and cartilage (SMR 9.59, 95%CI 1.54-59.77), and mesothelioma (SMR 13.07, 95%CI 1.61-105.80).
conclusionsoverall, meta-analyses underlined the relevance of suicide mortality in different cancer sites and geographical regions. Some meta-analyses also found suicidal ideation may be important in prostate or bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.